CME/CE Courses New

myCME Your search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.

Featured Courses

Maternal Alloimmunization and Hemolytic Disease of the Fetus and Newborn: Where We Are and Where We Need to Go

Maternal Alloimmunization and Hemolytic Disease of the Fetus and Newborn | myCME

1.50 CME CE: Interactive course discusses the pathogeneses of MA and HDFN, traditional management, and potential to integrate FcRn inhibitors. Exp 7/27/23

Reducing the Risk of Severe Illness for Patients with COVID-19: A TDT (Testing > Diagnosis > Treatment) Micro-Learning Library

Reducing the Risk of Severe Illness for Patients With COVID-19 | myCME

3.00 CME: This micro-learning library offers short podcasts and videos on testing, diagnosis, and treatment of COVID-19. Exp 8/30/23

Turning Talk Into Treatment: Applying New Evidence To Shared Decisions In Psoriatic Arthritis Care

Shared Decision Making In Psoriatic Arthritis Care | myCME

1.25 CME CE: Advances in therapies for PsA are promising. This CME activity aims to bridge the gap between available treatment options and patient care. 9/16/23

Racial and Ethnic Disparities and Health Inequities in Lung Cancer | myCME

0.75 CME CE: Expert faculty discuss biases, disparities, and health inequities for racial and ethnic underserved patients with lung cancer. Exp. 10/25/23

Managing Unhealthy Alcohol Use: Diagnosis and Treatment Retention | myCME

1.00 CME CE: Managing unhealthy alcohol use in clinical practice: best practices in diagnosis and treatment retention. Exp 2/24/24

Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics

Upstream Mediators With Next-Generation Biologics | myCME

0.75 CME: Provides clinicians with an understanding of the unmet needs in severe asthma, the alarmin pathway, and novel biologic therapies. Exp 7/29/23

Scleroderma-Associated Pulmonary Arterial Hypertension: Early Detection = Better Outcomes

Scleroderma-Associated PAH Early Detection | myCME

0.75 CME CNE: Interact with virtual patients as you manage scleroderma-associated pulmonary arterial hypertension with expert clinical mentoring. Exp. 9/14/23

Today and Tomorrow: Managing Resistance in Heavily ART-Experienced People with HIV

Managing Resistance in Heavily ART-Experienced People with HIV | myCME

0.75 CME CE: Faculty will present the latest information on the causes of ART resistance and medication non-adherence in patients with HIV and discuss the latest medication. Exp 1/18/24

Pediatric Influenza Vaccines: Examining Technology, Efficacy, and Outcomes

Pediatric Influenza Vaccines: Technology, Efficacy, Outcomes | myCME

0.75 CME CNE: Experts review egg-based inactivated, cell-culture–based inactivated, live attenuated pediatric flu vaccines; plus efficacy and improving immunization rates. Exp 10/30/23

The Latest Update on Metachromatic Leukodystrophy: Screening, Diagnosis, and Emerging Treatments to Improve Quality of Life of Patients

The Latest Update on Metachromatic Leukodystrophy | myCME

1.50 CME CE: Panelists discuss biomarkers that identify patients at the pre-symptomatic phase of metachromatic leukodystrophy. Exp. 12/6/23

Digital Pathway: Challenges and Advances in the Diagnosis and Management of Immune Thrombocytopenic Purpura

The Diagnosis and Management of Immune Thrombocytopenic Purpura | myCME

1.00 CME CE: Significant developments have been made recently in managing ITP and this activity will walk you through these advances and aid in improving care for these patients. Exp 9/18/23

Action Steps to Address Inequities in Cancer Care Access, Treatment, and Outcomes in Your Community

Steps to Address Inequities in Cancer Care Access | myCME

0.75 CME CE: Expert faculty discuss treatment obstacles many patients from underserved communities face for cancer therapies such as ICIs. Exp. 9/16/23

Click for More Courses

Next post in CME/CE Features